Submission Guidelines


While the AACE Abstracts Submission period may be closed, please take a moment to review all guidelines below. If eligible, you will have the opportunity to submit your abstract for the AACE 30th Annual Scientific & Clinical Congress in Las Vegas, NV, May 27-30, 2021.


    • Abstracts may be submitted by AACE members or non-members sponsored by an AACE member.
    • Abstracts describing original research, clinical trials, or case studies/series related to the area of endocrinology may be submitted.
    • Abstract submissions must be an original contribution and may not have previously been presented at any national U.S. meeting(s) (or published as a result of such a meeting) in the same format.
    • By submitting your abstract, you agree to present the abstract if it is selected for presentation during a poster presentation at EMBRAACE 2020 in Washington, DC.
    • All accepted abstracts will be published as an online supplement to Endocrine Practice.
    • If the abstract reports results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase.
    • There is no limit for the number of abstracts that can be submitted.
    • The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
    • Abstracts submitted for the late-breaking category cannot be submitted to another category.
    • Submitting authors who are not AACE members or do not have an AACE member sponsor will not be eligible to submit.
    • Abstracts that have been previously presented at any national U.S. meeting or published as a result of the meeting.


  • Adrenal Disorders
  • Calcium/Bone Disorders
  • Diabetes/Prediabetes/Hypoglycemia
  • Lipids/CV Health
  • Obesity/Nutrition
  • Parathyroid/Bone Disorders
  • Pituitary disorders/Neuroendocrinology
  • Reproductive Endocrinology
  • Thyroid
  • Other


The abstract limit is 2,700 characters, including spaces. Count excludes the title, names of authors/co-authors, authors’ affiliations and disclosures. Abstracts marked “incomplete” at the close of the submission deadline will be ineligible for consideration.

  • Titles should be brief, clearly indicating the nature of the presentation (Limited to 240 characters including spaces).
  • Trial group names should not appear in title.
  • When entering the abstract title online, use ALL caps and DO NOT put a period at the end of the title.
  • Enter the title in the “title” field only and do not enter the title in the body of the abstract.
  • Author names and affiliations should not appear in title.
  • Incorrect: This is an Improperly Formatted Abstract Title.
  • Submitting authors will be listed as the primary author on the abstract, NO EXCEPTIONS.
  • Do not list authors or commercial relationships in the body of the abstract. Please consult with your co-authors on how they would like their names to appear prior to the submission of the abstract.
  • Prior to submitting the abstract, please ensure that it is proofread by an individual who speaks fluent English and can make recommendations as needed.
  • Do not use new technical words, laboratory slang, words not defined in dictionaries, abbreviations, or terminology not consistent with internationally accepted guidelines. Define any abbreviations the first time they are used. Omit all names and geographical references in the body of the abstract. Organize content as follows:

      Original Research
    • Objective: Background or Statement of Purpose
    • Methods: Methods, materials and analytical procedure used
    • Results: Summary of the results in sufficient detail to support conclusion
    • Discussion: Discuss the content and interpret the data
    • Conclusion: Conclusions reached (do not state “results will be discussed”)

      Case Study
    • Introduction
    • Case description
    • Discussion
  • Use standard abbreviations. Place special or unusual abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.
  • AACE will only publish commonly used acronyms included in the unified list of acronyms approved by the principal journal editors in the field of endocrinology. Please refrain from using all trial group acronyms in abstract titles. Acronyms may remain in the body of the abstract and in the author list.
  • Tables, images, and/or graphs SHOULD NOT be submitted online. They may be included in the poster session.


AACE does not charge a processing fee for abstract submissions.


During submission, the author will be requested to agree to a copyright transfer if the abstract is accepted. The submitting author will agree to the terms of the copyright transfer on behalf of all co-authors. The agreement transfers to AACE the copyright and all other rights of the material comprising the abstract upon acceptance. The American Association of Clinical Endocrinologists, as holder of the copyright on the accepted abstract, reserves all right of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats. No patient rights are assigned.

For general inquiries regarding abstract submission, email or call (904) 353-7878.


Abstracts will be reviewed by the AACE Abstract Review Subcommittee and scored numerically 1 through 10 based on merit and significance to the science and practice of endocrinology, as well as their creativity and uniqueness.

  • “Incomplete” abstracts are considered incomplete and will not be reviewed. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the submission deadline – no exceptions.
  • All abstracts will be reviewed without knowledge of the author(s), institution(s) or disclosure information.
  • Accepted abstracts will be selected for publication only, poster presentation, or oral presentation.
  • Top scoring abstracts will be considered for oral presentation.


AACE members who are the primary author will be considered for travel grants.

  • 5 International Fellow-in-Training Travel Grants in the amount of $2,000
  • 1 International Non-Fellow Physician Travel Grant for $2,500
  • 5 Domestic Fellow-in-Training Travel Grants for $1,000 each *
  • 3 Domestic Resident Physician Travel Grants for internal medicine, pediatric, or surgical residents, includes a PAID two-night hotel stay and flights*
*To qualify for the Domestic Travel Grants, the Fellow-in-Training or Resident must be an AACE Member enrolled in a fellowship program or residency within the United States.


AACE will notify the primary author of the status of their abstract in early February. It is the primary author’s responsibility to then notify all co-authors. AACE requests that all interested parties please refrain from directly contacting the AACE offices to obtain information regarding abstract status, notification distribution and/or publication dates.

The submitting/primary author is the only author who will receive notification from AACE.


Poster display schedule will be finalized soon.

Poster specifications and onsite presentation details will be finalized soon.


A very limited number of abstracts may be selected for an Oral Presentation Session. Specific details regarding oral presentations will be sent to the primary authors of the selected abstract.



The AACE Annual Scientific & Clinical Congress is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American Association of Clinical Endocrinologists. The information and materials displayed and presented during this meeting are the property of AACE and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the American Association of Clinical Endocrinologists and the presenter. Any use of the program content for commercial purposes, which includes, but is not limited to oral presentations, audiovisual materials used by speakers, and program handouts without the written consent of AACE is prohibited. This policy applies before, during and after the meeting. AACE will enforce its intellectual property rights and penalize those who infringe upon it.


The names, insignias, logos and acronyms of AACE are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the express written permission of the American Association of Clinical Endocrinologists. Attendees who have questions about AACE’s copyright policy should contact


Credentialed media attend the annual meeting to cover stories for consumer, trade and other media outlets, and are easily identified by their media badges. Media have access to all general sessions, the exhibit hall and meet the professor and workshop sessions. Media may use a hand-held audio recording device during scientific and educational sessions for reference purposes to assist in writing stories. No part of audio recordings made during sessions may be used for broadcast purposes or other commercial use. Video recordings of sessions are not permitted in the session.  Attendees who have questions about AACE’s media policies should contact the public relations department at


As a courtesy to our presenters, AACE policy does not permit photographs or recordings during educational sessions, including poster sessions. The only exception without prior consent from the presenter, is for registered media, who should review their registration for more information.


Accepted abstracts are made available to the public online in advance of the meeting and will be published as a supplement to Endocrine Practice. Information contained in those abstracts may not be released until the date of poster presentations. Academic institutions, private organizations, and information contained in an abstract may issue a press release to coincide with the availability of an AACE abstract on the AACE website. However, AACE continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until 9:45 am ET on Thursday, May 7, 2020.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy.



All accepted abstracts will be available on the EMBRAACE website Thursday, May 7, 2020. They will be published as a supplement to Endocrine Practice.


Proofread abstracts carefully to avoid errors prior to submission. Your abstract, if selected, will be published exactly as submitted. You may return to the online submission site to revise your abstract until 11:59 pm ET on Wednesday, December 11, 2019. After this date/time, the submission site will close and no additional changes, edits, revisions, etc. can be made.

Should a submission contain errors or the omission of contributing author names after the deadline, presenters may opt to have the abstract withdrawn.


Primary authors may withdraw a completed abstract before December 11, 2019, by clicking on “Complete” in the Abstract Status line. You will be directed to a page that will allow you to select “Withdrawn” from a drop-down list of Abstract Status options. Please be sure to click on Update Abstract before leaving this page if you choose to withdraw your submission.

After December 11, 2019, presenting authors may submit a request to have an abstract withdrawn. All requests can only be made by the presenting author and must be submitted via e-mail to

Withdrawal requests must be received by February 17, 2020, and include the following:

  • Abstract ID Number
  • Abstract Title
  • Presenting Author’s Name
**The removal of the abstract from printed materials cannot be guaranteed if the request is received after February 17, 2020.


The late-breaking abstract category allows for the submission of truly late-breaking scientific research for which no preliminary data are available at the time of the Wednesday, December 11, 2019, abstract submission deadline.

Late-breaking abstracts should present data that is groundbreaking, innovative and has a high impact factor. This category is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the general abstract submission deadline.


The late-breaking abstract submission site will open on Wednesday, January 29, 2020, and close on Tuesday, March 3, 2020, at 11:59 pm ET. Submitters will not have access to the submission site after the submission deadline. Please check the EMBRAACE 2020 website for submission site link.

Late-breaking Abstracts will be published online before the annual meeting. Visit the EMBRAACE 2020 website in February for our official late-breaking abstracts launch announcement.


All presenting authors are required to register and pay the appropriate registration fees and arrange hotel accommodations.

Submitting an abstract or acceptance of an abstract does not register you or ensure hotel accommodations for the meeting.


January 29, 2020
Late-breaking abstract submission site opens

March 3, 2020
Late-breaking abstract submission site closes at 11:59 pm ET


May 6, 2020
Pre-Congress Sessions

May 7 – May 10, 2020Scientific Sessions